Department of Hepatobiliary Surgery, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
Department of Hepatobiliary Surgery, Tongnan District People's Hospital, Chongqing, China.
Mediators Inflamm. 2023 May 2;2023:7057236. doi: 10.1155/2023/7057236. eCollection 2023.
Hepatocellular carcinoma (HCC) is a malignancy with one of the worst prognoses. Long noncoding RNAs (lncRNAs) may be important in cancer development and may serve as new biomarkers for the diagnosis and treatment of various tumors, according to mounting research. The purpose of this study was to investigate the expression of INKA2-AS1 and clinical importance in HCC patients. The TCGA database was used to obtain the human tumor samples, while the TCGA and GTEx databases were used to gather the human normal samples. We screened differentially expressed genes (DEGs) between HCC and nontumor tissues. Investigations were made into the statistical significance and clinical significance of INKA2-AS1 expression. A single-sample gene set enrichment analysis (ssGSEA) was used to examine potential relationships between immune cell infiltration and INKA2-AS1 expression. In this investigation, we found that HCC specimens had considerably greater levels of INKA2-AS1 expression than nontumor specimens. When utilizing the TCGA datasets and the GTEx database, high INKA2-AS1 expression showed an AUC value for HCC of 0.817 (95% confidence interval: 0.779 to 0.855). Pan-cancer assays revealed that numerous tumor types had dysregulated levels of INKA2-AS1. Gender, histologic grade, and pathologic stage were all substantially correlated with high INKA2-AS1 expression. A survival study indicated that HCC patients with high INKA2-AS1 expression have shorter OS, DSS, and PFI than those with low INKA2-AS1 expression. Multivariate analysis indicated that INKA2-AS1 expression was an independent prognostic factor for OS of patients with HCC. According to immune analysis, the expression of INKA2-AS1 was favorably correlated with T helper cells, Th2 cells, macrophages, TFH, and NK CD56bright cells and negatively correlated with Th17 cells, pDC, cytotoxic cells, DC, Treg, Tgd, and Tcm. The results of this study collectively suggest that INKA2-AS1 has the potential to be a novel biomarker for predicting the prognosis of HCC patients as well as a significant immune response regulator in HCC.
肝细胞癌 (HCC) 是一种预后最差的恶性肿瘤之一。越来越多的研究表明，长链非编码 RNA (lncRNA) 可能在癌症的发展中起重要作用，并可能作为各种肿瘤的新的诊断和治疗标志物。本研究旨在探讨 INKA2-AS1 在 HCC 患者中的表达及其临床意义。TCGA 数据库用于获取人类肿瘤样本，而 TCGA 和 GTEx 数据库用于收集人类正常样本。我们筛选 HCC 组织与非肿瘤组织之间差异表达的基因 (DEGs)。研究 INKA2-AS1 表达的统计意义和临床意义。进行单样本基因集富集分析 (ssGSEA) 以研究免疫细胞浸润与 INKA2-AS1 表达之间的潜在关系。在本研究中，我们发现 HCC 标本中 INKA2-AS1 的表达明显高于非肿瘤标本。当使用 TCGA 数据集和 GTEx 数据库时，高 INKA2-AS1 表达对 HCC 的 AUC 值为 0.817（95%置信区间：0.779-0.855）。泛癌分析表明，许多肿瘤类型的 INKA2-AS1 表达失调。性别、组织学分级和病理分期与高 INKA2-AS1 表达显著相关。生存研究表明，INKA2-AS1 高表达的 HCC 患者的 OS、DSS 和 PFI 均短于 INKA2-AS1 低表达的患者。多变量分析表明 INKA2-AS1 表达是 HCC 患者 OS 的独立预后因素。根据免疫分析，INKA2-AS1 的表达与 Th 辅助细胞、Th2 细胞、巨噬细胞、TFH 和 NK CD56bright 细胞呈正相关，与 Th17 细胞、pDC、细胞毒性细胞、DC、Treg、Tgd 和 Tcm 呈负相关。本研究结果表明，INKA2-AS1 可能成为预测 HCC 患者预后的新型生物标志物，也是 HCC 中重要的免疫反应调节剂。
